Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PDGFRB Y562D |
| Therapy | Ruxolitinib |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PDGFRB Y562D | Advanced Solid Tumor | sensitive | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Jakafi (ruxolitinib) treatment inhibited phosphorylation of Jak2 and Stat1/3, proliferation, and migration in a cell line expressing PDGFRB Y562D in culture (PMID: 38741091). | 38741091 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (38741091) | Somatic PDGFRB activating variants promote smooth muscle cell phenotype modulation in intracranial fusiform aneurysm. | Full reference... |